Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (34.2), the stock would be worth ¥-38.01 (210% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -31 | ¥34.55 |
0%
|
| 3-Year Average | 34.2 | ¥-38.01 |
-210%
|
| 5-Year Average | 26.4 | ¥-29.36 |
-185%
|
| Industry Average | 23.9 | ¥-26.6 |
-177%
|
| Country Average | 28.8 | ¥-32.08 |
-193%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥16.2B
|
/ |
Oct 2025
¥-547.5m
|
= |
|
|
¥16.2B
|
/ |
Dec 2025
¥457.9m
|
= |
|
|
¥16.2B
|
/ |
Dec 2026
¥538.8m
|
= |
|
|
¥16.2B
|
/ |
Dec 2027
¥610.6m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Yipinhong Pharmaceutical Co Ltd
SZSE:300723
|
15.6B CNY | -31 | -36.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 28.4 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 16.9 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 15.6 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.2 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 9.7 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.2 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 7.5 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Yipinhong Pharmaceutical Co Ltd
Glance View
Yipinhong Pharmaceutical Co Ltd has carved its niche in the pharmaceutical landscape of China, with its roots embedded deeply in the nation's flourishing healthcare sector. Known for its dedication to combining traditional Chinese medicinal practices with modern scientific research, the company stands out in an increasingly competitive market. Yipinhong's operations are centered around developing, manufacturing, and distributing a broad spectrum of medicinal products that adhere to the highest quality standards. By focusing on therapeutic areas such as respiratory, cardiovascular, and gastrointestinal health, they strategically align with the growing demand for reliable medicinal solutions. What makes Yipinhong truly distinctive is its investment in research and development that drives innovation. This focus not only ensures a continuous pipeline of new products but positions them as a leader in the integration of traditional remedies with cutting-edge pharmaceutical science. The company thrives on a business model that maximizes its robust distribution network, encompassing both domestic and international markets. Yipinhong capitalizes on its vast network of sales agents and partnerships with hospitals, clinics, and pharmacies to ensure its products reach consumers efficiently. This network amplifies their revenue streams by tapping into various segments within the pharmaceutical supply chain. Moreover, Yipinhong's strategic collaborations for research and development and their participation in healthcare industry events bolster their market presence and brand recognition. By maintaining a harmonious balance between traditional approaches and modern demands, Yipinhong not only captures a unique market position but also sets a benchmark in pharmaceutical excellence and innovation.